AnaptysBio, Inc. (ANAB)
ANAB Stock Price Chart
Explore AnaptysBio, Inc. interactive price chart. Choose custom timeframes to analyze ANAB price movements and trends.
ANAB Company Profile
Discover essential business fundamentals and corporate details for AnaptysBio, Inc. (ANAB) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
26 Jan 2017
Employees
136.00
Website
https://www.anaptysbio.comCEO
Daniel R. Faga
Description
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
ANAB Financial Timeline
Browse a chronological timeline of AnaptysBio, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 4 May 2026
Upcoming earnings on 25 Feb 2026
Upcoming earnings on 4 Nov 2025
EPS estimate is -$1.31, while revenue estimate is $16.58M.
Earnings released on 6 Aug 2025
EPS came in at -$1.34 surpassing the estimated -$1.50 by +10.67%, while revenue for the quarter reached $22.26M , beating expectations by +6.94%.
Earnings released on 5 May 2025
EPS came in at -$1.28 surpassing the estimated -$1.30 by +1.54%, while revenue for the quarter reached $27.77M , beating expectations by +181.36%.
Earnings released on 27 Feb 2025
EPS came in at -$0.72 surpassing the estimated -$1.61 by +55.28%, while revenue for the quarter reached $43.11M , beating expectations by +453.91%.
Earnings released on 5 Nov 2024
EPS came in at -$1.14 surpassing the estimated -$1.72 by +33.72%, while revenue for the quarter reached $30.02M , beating expectations by +253.97%.
Earnings released on 5 Aug 2024
EPS came in at -$1.71 falling short of the estimated -$1.20 by -42.50%, while revenue for the quarter reached $10.97M , missing expectations by -54.85%.
Earnings released on 9 May 2024
EPS came in at -$1.64 falling short of the estimated -$1.54 by -6.49%, while revenue for the quarter reached $7.18M , beating expectations by +80.83%.
Earnings released on 11 Mar 2024
EPS came in at -$1.59 surpassing the estimated -$1.74 by +8.62%, while revenue for the quarter reached $9.01M , beating expectations by +343.60%.
Earnings released on 2 Nov 2023
EPS came in at -$1.41 surpassing the estimated -$1.72 by +18.02%, while revenue for the quarter reached $3.32M , beating expectations by +44.26%.
Earnings released on 7 Aug 2023
EPS came in at -$1.50 surpassing the estimated -$1.65 by +9.09%, while revenue for the quarter reached $3.46M , beating expectations by +4.22%.
Earnings released on 11 May 2023
EPS came in at -$1.58 falling short of the estimated -$1.04 by -51.92%, while revenue for the quarter reached $1.37M , missing expectations by -61.51%.
Earnings released on 1 Mar 2023
EPS came in at -$0.93 falling short of the estimated -$0.92 by -1.09%, while revenue for the quarter reached $6.81M , beating expectations by +17.71%.
Earnings released on 8 Nov 2022
EPS came in at -$1.18 falling short of the estimated -$0.47 by -151.06%, while revenue for the quarter reached $1.29M , missing expectations by -90.37%.
Earnings released on 8 Aug 2022
EPS came in at -$1.15 falling short of the estimated -$0.95 by -21.05%, while revenue for the quarter reached $1.22M , missing expectations by -77.04%.
Earnings released on 4 May 2022
EPS came in at -$1.31 falling short of the estimated -$0.87 by -50.57%, while revenue for the quarter reached $970.00K , missing expectations by -80.81%.
Earnings released on 7 Mar 2022
EPS came in at -$1.13 falling short of the estimated $2.28 by -149.56%, while revenue for the quarter reached $1.01M , beating expectations by +3.59%.
Earnings released on 4 Nov 2021
EPS came in at -$0.24 surpassing the estimated -$0.74 by +67.57%, while revenue for the quarter reached $20.89M , beating expectations by +174.87%.
Earnings released on 9 Aug 2021
EPS came in at -$0.02 surpassing the estimated -$0.15 by +86.67%, while revenue for the quarter reached $30.03M , beating expectations by +3.97%.
Earnings released on 4 May 2021
EPS came in at -$0.66 surpassing the estimated -$0.71 by +7.04%, while revenue for the quarter reached $11.25M , beating expectations by +18.39%.
Earnings released on 25 Feb 2021
EPS came in at $1.20 falling short of the estimated $1.39 by -13.67%, while revenue for the quarter reached $60.00M , beating expectations by +9.09%.
Earnings released on 4 Nov 2020
EPS came in at -$0.87 falling short of the estimated -$0.77 by -12.99%.
ANAB Stock Performance
Access detailed ANAB performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.